Covered recipient · General Payments record
NICHOLAS PENNINGS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$10,043.29
- Reported across 66 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $681.21 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $301.86 | 6 |
| Lilly USA, LLC | $137.36 | 6 |
| Acerta Pharma LLC | $123.19 | 1 |
| PFIZER INC. | $56.18 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $44.85 | 1 |
| Currax Pharmaceuticals LLC | $17.77 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $123.19 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104581986 | CMS |
| Currax Pharmaceuticals LLC | $17.77 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513976 | CMS |
| Lilly USA, LLC | $23.73 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135245853 | CMS |
| Lilly USA, LLC | $17.00 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135245858 | CMS |
| Lilly USA, LLC | $18.12 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135297008 | CMS |
| Lilly USA, LLC | $13.23 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135284913 | CMS |
| Lilly USA, LLC | $15.78 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135241671 | CMS |
| Lilly USA, LLC | $49.50 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135245861 | CMS |
| Novo Nordisk Inc | $21.63 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097105944 | CMS |
| Novo Nordisk Inc | $23.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097709722 | CMS |
| Novo Nordisk Inc | $19.23 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096630953 | CMS |
| Novo Nordisk Inc | $121.91 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096911367 | CMS |
| Novo Nordisk Inc | $112.39 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097768270 | CMS |
| Novo Nordisk Inc | $3.70 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096617802 | CMS |
| PFIZER INC. | $33.64 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131089456 | CMS |
| PFIZER INC. | $22.54 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131970506 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $44.85 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137652842 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.